{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:46Z","timestamp":1789726246189,"version":"4.0.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the risk of infectious complications associated with the use of ciprofloxacin (CIP) or fosfomycin-trometamol (FMT) for antibiotic prophylaxis in patients undergoing transrectal prostate biopsy (TrBx).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, single-centre analysis was conducted, including patients who underwent TrBx from 2015 to 2023 and received CIP or FMT for antimicrobial prophylaxis. The primary endpoint was symptomatic urinary tract infections within 30 days after TrBx, and the secondary endpoint was hospitalization due to infectious complications. Logistic regression was used to assess the risk of infection, adjusted for variables such as age, prostate size and comorbidities. Hospitalization rates were compared using the chi-square test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 913 patients were eligible for inclusion, of whom 491 had received CIP and 422 had received FMT. Infectious complications occurred in 38\/913 (4.2%) of all patients, 12\/491 (2.4%) of whom had received CIP and 26\/422 (6.2%) of whom had received FMT. Multivariable analysis revealed a significantly greater risk of infectious complications with FMT (adjusted odds ratio 2.99, 95% CI 1.39\u20137.16,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.008) compared to CIP. Hospitalization rates were similar in the CIP group (8\/12, 66.6%) and FMT group (14\/26, 53.5%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.7), but one death occurred due to fulminant sepsis in the FMT group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared with CIP, FMT prophylaxis is associated with a greater risk of infectious complications and should be used cautiously in routine clinical practice. Given the uncertainty of FMT\u2019s efficacy in preventing infections after TrBx, alternative antibiotic regimens should be preferred, or transitioning to the transperineal biopsy approach may further reduce infection risk and support antibiotic stewardship.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-025-05818-8","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T10:18:41Z","timestamp":1753525121000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Infectious complications in patients undergoing transrectal prostate-biopsy with ciprofloxacin compared to fosfomycin-trometamol"],"prefix":"10.1007","volume":"43","author":[{"given":"Andreas","family":"Banner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Ubber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Stoces","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Madersbacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Grabovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"key":"5818_CR1","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.ejca.2021.07.039","volume":"157","author":"T Dyba","year":"2021","unstructured":"Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N et al (2021) The European cancer burden in 2020: incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer 157:308\u2013347","journal-title":"Eur J Cancer"},{"issue":"5","key":"5818_CR2","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1016\/j.juro.2011.06.057","volume":"186","author":"S Loeb","year":"2011","unstructured":"Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM (2011) Complications after prostate biopsy: data from SEER-Medicare. J Urol 186(5):1830\u20131834","journal-title":"J Urol"},{"issue":"2","key":"5818_CR3","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, Van Den Bergh RCN, Briers E, Van Den Broeck T, Brunckhorst O, Darraugh J et al (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate Cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 86(2):148\u2013163","journal-title":"Eur Urol"},{"issue":"3","key":"5818_CR4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/JU.0000000000001399","volume":"205","author":"B Pradere","year":"2021","unstructured":"Pradere B, Veeratterapillay R, Dimitropoulos K, Yuan Y, Omar MI, MacLennan S et al (2021) Nonantibiotic strategies for the prevention of infectious complications following prostate biopsy: A systematic review and Meta-Analysis. J Urol 205(3):653\u2013663","journal-title":"J Urol"},{"issue":"2","key":"5818_CR5","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/JU.0000000000000814","volume":"204","author":"A Pilatz","year":"2020","unstructured":"Pilatz A, Dimitropoulos K, Veeratterapillay R, Yuan Y, Omar MI, MacLennan S et al (2020) Antibiotic prophylaxis for the prevention of infectious complications following prostate biopsy: A systematic review and Meta-Analysis. J Urol 204(2):224\u2013230","journal-title":"J Urol"},{"issue":"2","key":"5818_CR6","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00210-023-02622-2","volume":"397","author":"P Serwacki","year":"2024","unstructured":"Serwacki P, Gajda M, \u015awi\u0105tek-Kwapniewska W, Wa\u0142aszek M, Nowak K, W\u00f3jkowska-Mach J (2024) Re-evaluating the suitability of using fluoroquinolones in the treatment of infections in the context of FQ consumption and correlating changes to microorganism resistance levels in EU\/EEA countries between 2016 and 2021. Naunyn Schmiedebergs Arch Pharmacol 397(2):795\u2013805","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"5818_CR7","unstructured":"European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics [Internet] (2019) Report No.: EMA\/175398\/2019. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/quinolone-and-fluoroquinolone-article-31-referral-disabling-and-potentially-permanent-side-effects-lead-suspension-or-restrictions-quinolone-and-fluoroquinolone-antibiotics_en.pdf"},{"issue":"1","key":"5818_CR8","first-page":"1","volume":"28","author":"S Sergio","year":"2020","unstructured":"Sergio S, Tan KM, Reyes S (2020) The use of fosfomycin as preoperative antibiotic prophylactic for transrectal Ultrasound-Guided prostate needle biopsy: A randomized, controlled clinical study in veterans memorial medical center. Philipp J Urol 28(1):1\u20136","journal-title":"Philipp J Urol"},{"issue":"11\u201312","key":"5818_CR9","doi-asserted-by":"publisher","first-page":"863","DOI":"10.5489\/cuaj.3068","volume":"9","author":"V Sen","year":"2015","unstructured":"Sen V, Aydogdu O, Bozkurt IH, Yonguc T, Sen P, Polat S et al (2015) The use of prophylactic single-dose fosfomycin in patients who undergo transrectal ultrasound-guided prostate biopsy: A prospective, randomized, and controlled clinical study. Can Urol Assoc J 9(11\u201312):863","journal-title":"Can Urol Assoc J"},{"issue":"6","key":"5818_CR10","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.acuro.2014.01.002","volume":"38","author":"F Lista","year":"2014","unstructured":"Lista F, Redondo C, Meil\u00e1n E, Garc\u00eda-Tello A, De Ram\u00f3n F, Angulo JC (2014) Eficacia y Seguridad de fosfomicina-trometamol En La profilaxis de La biopsia transrectal de La pr\u00f3stata: estudio prospectivo Aleatorizado comparativo Con Ciprofloxacino. Actas Urol Esp 38(6):391\u2013396","journal-title":"Actas Urol Esp"},{"key":"5818_CR11","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jgar.2018.11.020","volume":"17","author":"A Carignan","year":"2019","unstructured":"Carignan A, Sabbagh R, Masse V, Gagnon N, Montpetit LP, Smith MA et al (2019) Effectiveness of fosfomycin tromethamine prophylaxis in preventing infection following transrectal ultrasound-guided prostate needle biopsy: results from a large Canadian cohort. J Glob Antimicrob Resist 17:112\u2013116","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"5818_CR12","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.prnil.2023.11.003","volume":"12","author":"Y Chung","year":"2024","unstructured":"Chung Y, Hong SK (2024) Shifting to transperineal prostate biopsy: A narrative review. Prostate Int 12(1):10\u201314","journal-title":"Prostate Int"},{"key":"5818_CR13","doi-asserted-by":"crossref","unstructured":"Ononye R, Roberts J, Igbokwe K, Adebisi AA, Adefehinti M Outcomes of Systematic Transrectal Ultrasound-Guided Prostate Biopsy Performed by a Surgical Care Practitioner and Implications for Resource-Poor Countries. Cureus [Internet]. 2024 Nov 26 [cited 2025 Jan 5]; Available from: https:\/\/www.cureus.com\/articles\/319414-outcomes-of-systematic-transrectal-ultrasound-guided-prostate-biopsy-performed-by-a-surgical-care-practitioner-and-implications-for-resource-poor-countries","DOI":"10.7759\/cureus.74488"},{"issue":"2","key":"5818_CR14","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s40140-021-00511-z","volume":"12","author":"M Moster","year":"2022","unstructured":"Moster M, Bolliger D (2022) Perioperative guidelines on antiplatelet and anticoagulant agents: 2022 update. Curr Anesthesiol Rep 12(2):286\u2013296","journal-title":"Curr Anesthesiol Rep"},{"issue":"2","key":"5818_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205\u2013213","journal-title":"Ann Surg"},{"key":"5818_CR16","doi-asserted-by":"crossref","unstructured":"Little RJA, Rubin DB (2020) Statistical analysis with missing data. 3rd edition. Hoboken, NJ: Wiley; 1 p. (Wiley series in probability and statistics)","DOI":"10.1002\/9781119482260"},{"issue":"1","key":"5818_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfab158","volume":"15","author":"NC Chesnaye","year":"2022","unstructured":"Chesnaye NC, Stel VS, Tripepi G, Dekker FW, Fu EL, Zoccali C et al (2022) An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J 15(1):14\u201320","journal-title":"Clin Kidney J"},{"issue":"2","key":"5818_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/JU.0000000000003788","volume":"211","author":"BM Mian","year":"2024","unstructured":"Mian BM, Feustel PJ, Aziz A, Kaufman RP, Bernstein A, Avulova S et al (2024) Complications following transrectal and transperineal prostate biopsy: results of the ProBE-PC randomized clinical trial. J Urol 211(2):205\u2013213","journal-title":"J Urol"},{"issue":"2","key":"5818_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00345-016-1867-6","volume":"35","author":"T Cai","year":"2017","unstructured":"Cai T, Gallelli L, Cocci A, Tiscione D, Verze P, Lanciotti M et al (2017) Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alternative. World J Urol 35(2):221\u2013228","journal-title":"World J Urol"},{"issue":"3","key":"5818_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00345-017-2163-9","volume":"36","author":"MJ Roberts","year":"2018","unstructured":"Roberts MJ, Scott S, Harris PN, Naber K, Wagenlehner FME, Doi SAR (2018) Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis. World J Urol 36(3):323\u2013330","journal-title":"World J Urol"},{"issue":"11","key":"5818_CR21","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.3390\/microorganisms12112320","volume":"12","author":"AP Ruiz-Lievano","year":"2024","unstructured":"Ruiz-Lievano AP, Cervantes-Flores F, Nava-Torres A, Carbajal-Morales PJ, Villase\u00f1or-Garcia LF, Zavala-Cerna MG (2024) Fluoroquinolone resistance in Escherichia coli causing Community-Acquired urinary tract infections: A systematic review. Microorganisms 12(11):2320","journal-title":"Microorganisms"},{"issue":"1","key":"5818_CR22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s43856-023-00337-2","volume":"3","author":"V Tchesnokova","year":"2023","unstructured":"Tchesnokova V, Larson L, Basova I, Sledneva Y, Choudhury D, Solyanik T et al (2023) Increase in the community circulation of ciprofloxacin-resistant Escherichia coli despite reduction in antibiotic prescriptions. Commun Med 3(1):110","journal-title":"Commun Med"},{"issue":"6","key":"5818_CR23","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/clpt.1989.204","volume":"46","author":"GS Hughes","year":"1989","unstructured":"Hughes GS, Heald DL, Barker KB, Patel RK, Spillers CR, Watts KC et al (1989) The effects of gastric pH and food on the pharmacokinetics of a new oral cephalosporin, Cefpodoxime proxetil. Clin Pharmacol Ther 46(6):674\u2013685","journal-title":"Clin Pharmacol Ther"},{"key":"5818_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.urology.2016.12.011","volume":"104","author":"MJ Roberts","year":"2017","unstructured":"Roberts MJ, Bennett HY, Harris PN, Holmes M, Grummet J, Naber K et al (2017) Prostate Biopsy-related infection: A systematic review of risk factors, prevention strategies, and management approaches. Urology 104:11\u201321","journal-title":"Urology"},{"issue":"1","key":"5818_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.eururo.2023.12.015","volume":"86","author":"JC Hu","year":"2024","unstructured":"Hu JC, Assel M, Allaf ME, Ehdaie B, Vickers AJ, Cohen AJ et al (2024) Transperineal versus transrectal magnetic resonance Imaging\u2013targeted and systematic prostate biopsy to prevent infectious complications: the PREVENT randomized trial. Eur Urol 86(1):61\u201368","journal-title":"Eur Urol"},{"issue":"1","key":"5818_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bju.15039","volume":"126","author":"B Berry","year":"2020","unstructured":"Berry B, Parry MG, Sujenthiran A, Nossiter J, Cowling TE, Aggarwal A et al (2020) Comparison of complications after transrectal and transperineal prostate biopsy: a National population-based study. BJU Int 126(1):97\u2013103","journal-title":"BJU Int"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05818-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-05818-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-05818-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:02:30Z","timestamp":1767996150000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-05818-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5818"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-05818-8","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,26]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Was granted by the ethics committee of the city of Vienna, MA 15 (EK 24-152-VK).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"460"}}